Randomised Clinical Study to Evaluate the Use of Tilapia Skin (Oreochromis Niloticus), as an Occlusive Biological Dressing, in the Treatment of Burn Wounds
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 63
- 主要终点
- Amount of anesthetics or analgesics used throughout the treatment in study C
研究概览
简要总结
Randomised Clinical Study to evaluate the efficacy of Nile tilapia (Oreochromis niloticus) skin as an occlusive biological dressing, in the treatment of humans burn wounds.
详细描述
This was a randomized, monocentric; open-label pilot clinical study conducted at the Dr. José Frota Institute's Burn Treatment Center, located in Fortaleza, Ceará, Brazil, from October 2016 to September 2017.
The study participants were recruited from the population of patients attending the Burning Treatment Center of the Dr. José Frota Institute. Were included female and male participants, age range greater than or equal to 18 and greater than or equal to 50 years old and who met the following criteria: presence of a dermatological wound caused by superficial second-degree burn with up to 20% of the body surface or deep second degree with area of 5 to 15% of the body surface; absence of previous treatment for the current burn and without other significant diseases that could impact their participation in the study. No study participants were known to have hypersensitivity to materials used in the study or to related compounds; history of serious adverse reactions; addiction to drugs, including alcohol; pregnancy and labor or miscarriage in the 12 weeks prior to the scheduled start of treatment.
The study was divided according to the depth and burned body surface area of the research participant:
Study A: Burning of 2nd Surface Degree with <10% of body surface area - Patients in outpatient care, within this group, the research participants were randomly assigned to the following treatment groups: active comparator (sulfadiazine, Silver) or experimental (skin of Nile tilapia).
Study B: 2nd Degree Burn with 10 to 20% body surface area - Inpatient, within this group, the research participants were randomly assigned to the following treatment groups: active comparator (sulfadiazine, Silver) or experimental (skin of Nile tilapia).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of a dermatological wound caused by superficial second-degree burn with up to 20% of the body surface or deep second degree with area of 5 to 15% of the body surface;
- •Absence of previous treatment for the current burn
- •Without other significant diseases that could impact their participation in the study
排除标准
- •Hypersensitivity to materials used in the study or to related compounds;
- •History of serious adverse reactions;
- •Addiction to drugs, including alcohol;
- •Pregnancy
- •Labor or miscarriage in the 12 weeks prior to the scheduled start of treatment.
研究组 & 干预措施
Sulfadiazine, Silver
Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
干预措施: Sulfadiazine, Silver (Drug)
Skin of Nile tilapia
Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered).
干预措施: Skin of Nile tilapia (Device)
结局指标
主要结局
Amount of anesthetics or analgesics used throughout the treatment in study C
时间窗: Day 21
Use of anesthetics or analgesics required for the change of dressings performed throughout the treatment.
Number of days for complete re-epithelization in study A and B
时间窗: Day 11
Number of days until complete re-epithelialization observed by the evaluator
Number of days for complete re-epithelization in study C
时间窗: Day 21
Number of days until complete re-epithelialization observed by the evaluator
The number of dressings performed as needed in study C
时间窗: Day 21
Relation to the number of dressings performed in patients treated with Silver Sulfadiazine and Tilapia Skin throughout the treatment.
Amount of anesthetics or analgesics used throughout the treatment in study A and B
时间窗: Day 11
Use of anesthetics or analgesics required for the change of dressings performed throughout the treatment.
The number of dressings performed as needed in study A and B
时间窗: Day 11
Relation to the number of dressings performed in patients treated with Silver Sulfadiazine and Tilapia Skin throughout the treatment.
次要结局
- Change in patient global assessment scores(Day 1, 3, 5, 7, 9, 11, 15 and 30 (group A and B) and day 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25 and 40 (group C).)
- Change in Global Clinical Impression Scale - Disease Severity (CGI-S) scores(Day 1, 3, 5, 7, 9, 11, 15 and 30 (group A and B) and day 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25 and 40 (group C).)
- Change in Global Clinical Impression Scale - Disease Improvement (CGI-I) scores(Day 1, 3, 5, 7, 9, 11, 15 and 30 (group A and B) and day 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25 and 40 (group C).)
- Change in scale of pain by the Visual Analogue Scale(Day 1, 3, 5, 7, 9, 11, 15 and 30 (group A and B) and day 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25 and 40 (group C).)
研究者
Edmar Maciel Lima Júnior
MD, Plastic Surgeon
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
